Beatriz E. Adrada, M.D.

Peer-Reviewed Articles

1. Xu Z, Zhou Z, Son JB, Feng H, Adrada BE, Moseley T, Candelaria RP, Guirguis M, Patel MM, Whitman GJ, Leung JWT, Le-Petross HT, Mohamed RM, Panthi B, Lane DL, Chen H, Wei P, Tripathy D, Litton JK, Valero V, Huo L, Hunt KK, Korkut A, Thompson A, Yang W, Yam C, Rauch GM, Ma J. Deep learning models based on pretreatment MRI and clinicopathological data to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Cancers, 2025. e-Pub 2025.
2. Fazeli S, Stepenosky J, Guirguis MS, Adrada BE, Rakow-Penner R, Ojeda-Fournier H. Understanding BI-RADS Category 3. Radiographics 45(1):e240169, 2025. e-Pub 2025. PMID: 39636752.
3. Patel MM, Adrada BE, Guirguis MS, Whitman G, Moseley TW, Rauch GM. Current Concepts in Molecular Breast Imaging. Journal of Breast Imaging 7(1):104-118, 2024. e-Pub 2024. PMID: 39692400.
4. Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
5. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging 60(4):1367-1376, 2024. e-Pub 2024. PMID: 38294179.
6. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
7. Marques-Piubelli ML, Lyapichev KA, Fnu A, Adrada B, Stewart J, Hunt KK, Clemens MW, Iyer S, Wu Y, El Hussein S, Xu J, Ok CY, Li S, Pierson DM, Ferrufino-Schmidt MC, Nahmod KA, Yoga A, Hunsicker L, Evans MG, Resetkova E, Qiu L, Khanlari M, Garces SA, Bueso-Ramos CE, Medeiros LJ, Miranda RN. The Spectrum of Non-neoplastic Changes Associated With Breast Implants: Histopathology, Imaging, and Clinical Significance. Am J Surg Pathol 48(6):e43-e64, 2024. e-Pub 2024. PMID: 38451836.
8. Guirguis MS, Arribas EM, Kapoor MM, Patel MM, Perez F, Nia ES, Ding Q, Moseley TW, Adrada BE. Multimodality Imaging of Benign and Malignant Diseases of the Nipple-Areolar Complex. Radiographics 44(4), 2024. e-Pub 2024. PMID: 38483829.
9. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
10. Garber HR, Basu S, Jindal S, He Z, Chu K, Raghavendra AS, Yam C, Santiago L, Adrada BE, Sharma P, Mittendorf EA, Litton JK. Durvalumab and Tremelimumab Before Surgery in Patients with Hormone Receptor Positive, HER2-Negative Stage II-III Breast Cancer. Oncotarget 15(15):238-247, 2024. e-Pub 2024. PMID: 38502947.
11. Patel MM, Adrada BE, Nia ES, Kapoor KM, Khazai L, Guirguis MS, Perez F, Moseley TW, Arribas EM. Multimodality Imaging of Breast Cancer Recurrence Post Breast Conservation Therapy. Curent Radiology Reports 12(2):9-18, 2024. e-Pub 2024.
12. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
13. Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS. Triple-negative breast cancer: Histopathologic features, genomics, and treatment. RadioGraphics 43(10), 2023. e-Pub 2023. PMID: 37792593.
14. Xu Z, Rauch DE, Mohamed RM, Pashapoor S, Zhou Z, Panthi B, Son JB, Hwang KP, Musall BC, Adrada BE, Candelaria RP, Leung JWT, Le-Petross HTC, Lane DL, Perez F, White J, Clayborn A, Reed B, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J. Deep learning for fully automatic tumor segmentation on serially acquired dynamic contrast-enhanced MRI images of triple-negative breast cancer. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835523.
15. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Moseley TW, Leung JW, Huang M, Candelaria RP, Adrada BE, et al. Patient-reported outcomes of omission of breast surgery following neoadjuvant systemic therapy a nonrandomized clinical trial. JAMA Netw Open 6(9), 2023. e-Pub 2023. PMID: 37707811.
16. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: Protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15, 2023. e-Pub 2023. PMID: 37547448.
17. Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. A radiomics model based on synthetic MRI acquisition for predicting neoadjuvant systemic treatment response in triple-negative breast cancer. Radiol Imaging Cancer 5(4):e230009, 2023. e-Pub 2023. PMID: 37505106.
18. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc 2023:1-4, 2023. e-Pub 2023. PMID: 38083160.
19. Engel AJ, Shin K, Adrada BE, Moseley TW, Krishnamurthy S, Whitman GJ. Review of the sonographic features of interpectoral (rotter) lymph nodes in breast cancer staging. Ultrasound Q 39(2):69-73, 2023. e-Pub 2022. PMID: 35439235.
20. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
21. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive roles of baseline stromal tumor-infiltrating lymphocytes and Ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
22. Engel AJ, Shin K, Adrada BE, Moseley TW, Krishnamurthy S, Whitman GJ. Review of the sonographic features of interpectoral (Rotter) lymph nodes in breast cancer staging. Ultrasound Quarterly 39(2):69-73, 2023. e-Pub 2023.
23. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
24. Weaver OO, Yang WT, Scoggins ME, Adrada BE, Arribas E, Moseley TW, Esquivel J, Melgar Y, Kornecki A. Challenging contrast-enhanced mammography-guided biopsies: practical approach using real-time multimodality imaging and a proposed procedural algorithm. AJR Am J Roentgenol 220(4):512-523, 2023. e-Pub 2023. PMID: 36321982.
25. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of response to neoadjuvant systemic treatment in triple-negative breast cancer using functional tumor volumes from longitudinal dynamic contrast-enhanced MRI. Cancers (Basel) 15(4):1025, 2023. e-Pub 2023. PMID: 36831368.
26. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer 9(9):2, 2023. e-Pub 2023. PMID: 36627285.
27. Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 13:1264259, 2023. e-Pub 2023. PMID: 37941561.
28. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, on behalf of the Exceptional Responders Clinical Trials Group: Moseley TW, Parra R, Adrada BE, Leung JWT, Sun SX, Teshome M, Miggins MV, Hunt KK, DeSnyder SM, Ehlers RA, Hwang RF, Colen JS, Arribas E, Samiian L, Lesnikoski B, Piotrowski M, Bedrosian I, Chong C, Refinetti AP, Huang M, Candelaria RP, Loveland-Jones C, Mitchell MP, Shaitelman SF. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: A multicenter, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
29. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative apparent diffusion coefficients from peritumoral regions as early predictors of response to neoadjuvant systemic therapy in triple-negative breast cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
30. Lopez BP, Rauch GM, Adrada B, Kappadath SC. Functional tumor diameter measurement with molecular breast imaging: Development and clinical application. Biomed Phys Eng Express 8(5), 2022. e-Pub 2022. PMID: 35917778.
31. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. e-Pub 2022. PMID: 35914239.
32. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res 28(17):3669-3676, 2022. e-Pub 2022. PMID: 35736816.
33. Hruska CB, Corion C, Geus-Oei LF, Adrada BE, Fowler AM, Hunt KN, Kappadath SC, Pilkington P, Pereira Arias-Bouda LM, Rauch GM. SNMMI procedure standard/EANM practice guideline for molecular breast imaging with dedicated y-cameras. Journal of Nuclear Medicine Technology 50(2):103-110, 2022. e-Pub 2022.
34. Huang M, Hess K, Ma J, Santiago L, Scoggins ME, Arribas E, Adrada BE, Le-Petross H, Leung JWT, Yang W, Geiser W, Candelaria RP. Prospective comparison of synthesized mammography with DBT and full-field digital mammography with DBT uncovers recall disagreements that may impact cancer detection. Academic Radiology 29(7):1039-1045, 2022. e-Pub 2022. PMID: 34538550.
35. Noreña-Rengifo BD, Sanín-Ramírez MP, Adrada BE, Luengas AB, Martínez de Vega V, Guirguis MS, Saldarriaga-Uribe C. MRI for evaluation of complications of breast augmentation. Radiographics 42(4):210096, 2022. e-Pub 2022. PMID: 35559662.
36. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
37. Hruska, CB, Corion, C, de Geus-Oei, LF, Adrada, BE, Fowler, AM, Hunt, KN, Kappadath, SC, Pilkington, P, Pereira Arias-Bouda, LM, Rauch, GM. SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated g-Cameras. Journal of nuclear medicine technology 50(2):103-110, 2022. e-Pub 2022.
38. Candelaria RP, Adrada BE, Lane DL, Rauch GM, Moulder SL, Thompson AM, Bassett RL, Arribas EM, Le-Petross HT, Leung JWT, Spak DA, Ravenberg EE, White JB, Valero V, Yang WT. Midtreatment ultrasound descriptors as qualitative imaging biomarkers of pathologic complete response in patients with triple negative breast cancer. Ultrasound Med Biol 48(6):1010-1018, 2022. e-Pub 2022. PMID: 35300879.
39. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149:110220, 2022. e-Pub 2022. PMID: 35193025.
40. Adrada BE, Guirguis MS, Hoang T, Spak DA, Rauch GM, Moseley TW. MRI-guided breast biopsy case-based review: Essential techniques and approaches to challenging cases. Radiographics 42(2):210126, 2022. e-Pub 2022. PMID: 35119965.
41. Guirguis MS, Adrada BE, Scoggins ME, Moseley TW, Whitman GJ. Reply to "additional references relevant to preoperative breast lesion localization techniques". AJR Am J Roentgenol 218(3):1, 2022. e-Pub 2022. PMID: 35107309.
42. Guirguis MS, Adrada BE, Scoggins ME, Moseley TW, Dryden MJ, Le-Petross HC, Rauch GM, Whitman GJ. The challenging image-guided preoperative breast localization: A modality-based approach. AJR Am J Roentgenol 218(3):423-434, 2022. e-Pub 2022. PMID: 34612680.
43. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
44. Guirguis MS, Checka C, Adrada BE, Whitman GJ, Dryden MJ, Sun J, Ding QQ, Le-Petross H, Rauch GM, Clemens M, Moseley TW. Bracketing with multiple radioactive seeds to achieve negative margins in breast conservation surgery: Multiple seeds in breast surgery. Clin Breast Cancer 22(2):e158-e166, 2022. e-Pub 2022. PMID: 34187752.
45. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS ultrasound lexicon descriptors and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer. Acad Radiol 29:S35-S41, 2022. e-Pub 2021. PMID: 34272161.
46. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Front Artif Intell 5:876100, 2022. e-Pub 2022. PMID: 36034598.
47. Adrada BE, Karbasian N, Huang M, Rauch GM, Woodtichartpreecha P, Whitman G. Imaging surveillance of the reconstructed breast in a subset of patients may aid in early detection of breast cancer recurrence. J Clin Imaging Sci 11(1):1-6, 2021. e-Pub 2021.
48. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy in triple-negative breast cancer using amide proton transfer-weighted chemical exchange saturation transfer MRI: A pilot study. Radiol Imaging Cancer 3(5):e200155, 2021. e-Pub 2021. PMID: 34477453.
49. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. e-Pub 2021. PMID: 33878210.
50. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
51. Bragg A, Candelaria R, Adrada B, Huang M, Rauch G, Santiago L, Scoggins M, Whitman G. Imaging of noncalcified ductal carcinoma in situ. J Clin Imaging Sci 11(34), 2021. e-Pub 2021.
52. Guirguis MS, Adrada B, Santiago L, Candelaria R, Arribas E. Mimickers of breast malignancy: Imaging findings, pathologic concordance and clinical management. Insights Imaging 12(1):53, 2021. e-Pub 2021. PMID: 33877461.
53. Nia ES, Adrada BE, Whitman GJ, Candelaria RP, Krishnamurthy S, Bassett RL, M Arribas E. MRI features of pseudoangiomatous stromal hyperplasia with histopathological correlation. Breast J 27(3):242-247, 2021. e-Pub 2021. PMID: 33393706.
54. Guirguis MS, Adrada BE, Surasi DS, Dryden MJ. 68Ga-DOTATATE Uptake in Primary Breast Cancer. Clin Nucl Med 46(3):248-249, 2021. e-Pub 2021. PMID: 33234932.
55. Adrada, BE, Karbasian, N, Huang, ML, Rauch, GM, Woodtichartpreecha, P, Whitman, GJ. Imaging surveillance of the reconstructed breast in a subset of patients may aid in early detection of breast cancer recurrence. Journal of Clinical Imaging Science 11, 2021. e-Pub 2021. PMID: 34877066.
56. Bragg, AC, Candelaria, RP, Adrada, BE, Huang, ML, Rauch, GM, Santiago, L, Scoggins, ME, Whitman, GJ. Imaging of noncalcified ductal carcinoma in situ. Journal of Clinical Imaging Science 11, 2021. e-Pub 2021. PMID: 34221643.
57. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol 130:109170, 2020. e-Pub 2020. PMID: 32777736.
58. Adrada BE, Moseley T, Kappadath SC, Whitman GJ, Rauch GM. Molecular breast imaging- guided percutaneous biopsy of breast lesions: A new frontier on breast intervention. J Breast Imaging 2(5):1-8, 2020. e-Pub 2020. PMID: 33015619.
59. Abdelhafez AH, Musall BC, Adrada BE, Hess KR, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang W, Rauch GM. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Breast Cancer Res Treat, 2020. e-Pub 2020.
60. Yalniz C, Meis JM, Wang WL, Huo L, Candelaria RP, Adrada BE, Lane D, Santiago L, Huang ML. Proliferative fasciitis mimicking sarcoma in the breast. Breast J:2072-2074. e-Pub 2020. PMID: 32854140.
61. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant (gBRCA+). J Clin Oncol 38(5):JCO1901304, 2020. e-Pub 2020. PMID: 31461380.
62. Sen LQC, Huang ML, Leung JWT, Wei W, Adrada BE. Malignancy rates of stereotactic biopsies of two or more distinct sites of suspicious calcifications in women without known breast cancer. Clin Imaging 58:156-160, 2019. e-Pub 2019. PMID: 31376706.
63. Yalniz C, Rosenblat J, Spak D, Wei W, Scoggins M, Le-Petross C, Dryden MJ, Adrada B, Dogan BE. Association of retrospective peer review and positive predictive value of magnetic resonance imaging-guided vacuum-assisted needle biopsies of breast. Eur J Breast Health 15(4):229-234, 2019. e-Pub 2019. PMID: 31620681.
64. Speer ME, Adrada BE, Arribas EM, Hess KR, Middleton LP, Whitman GJ. Imaging of intracystic papillary carcinoma. Curr Probl Diagn Radiol 48(4):348-352, 2019. e-Pub 2019. PMID: 30072190.
65. Adrada BE, Rauch GM. Molecular breast imaging in evaluating breast cancer extent of disease. J Breast Imaging 1(2):155-156, 2019. e-Pub 2019.
66. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114:167-174. e-Pub 2019. PMID: 31005169.
67. Tayyab SJ, Adrada BE, Rauch GM, Yang WT. A pictorial review: Multimodality imaging of benign and suspicious features of fat necrosis in the breast. Br J Radiol 91(1092):20180213, 2018. e-Pub 2018. PMID: 29987981.
68. Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. High risk breast lesions identified on magnetic resonance imaging-guided vacuum-assisted needle biopsy: Outcome of surgical excision and imaging follow-up. Br J Radiol 91(1090):20180300, 2018. e-Pub 2018. PMID: 29947265.
69. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrada BE, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding implementation of ACOSOG Z0011 in surgeon practice. Clinial Breast Cancer 18(4):276-281, 2018. e-Pub 2018. PMID: 29100726.
70. Rauch GM, Kuerer HM, Adrada BE, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: Imaging assessment and correlation endpoints. Ann Surg Oncol 25(7):1953-1960, 2018. e-Pub 2018. PMID: 29667115.
71. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2018. PMID: 28549010.
72. Kalambo M, Adrada BE, Adeyefa MM, Krishnamurthy S, Hess K, Carkaci S, Whitman GJ. Phyllodes tumor of the breast: Ultrasound-pathology correlation. AJR Am J Roentgenol 210(4):W173-W179, 2018. e-Pub 2018. PMID: 29412020.
73. Candelaria RP, Hansakul P, Thompson AM, Le-Petross H, Valero V, Bassett R, Huang ML, Santiago L, Adrada BE. Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. Am J Surg 215(4):693-698, 2018. e-Pub 2018. PMID: 28712671.
74. Candelaria RP, Krishnamurthy S, Huang ML, Santiago L, Adrada BE. Imaging and pathological findings in a case of invasive squamous cell carcinoma of the breast. Breast J 24(2):203-204, 2018. e-Pub 2018. PMID: 28727282.
75. Adrada BE, Candelaria R, Rauch GM. MRI for the staging and evaluation of response to therapy in breast cancer. Top Magn Reason Imaging 26(5):211-218, 2017. e-Pub 2017. PMID: 28961570.
76. Huang ML, Hess K, Candelaria RP, Eghtedari M, Adrada BE, Sneige N, Fornage BD. Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge, and 18-gauge automated cutting needle biopsy devices, and review of the literature. Eur Radiol 27(7):2928-2933, 2017. e-Pub 2017. PMID: 27844099.
77. Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-concordant benign magnetic resonance imaging-guided vacuum-assisted breast biopsy may not warrant magnetic resonance imaging follow-up. AJR Am J Roentgenol 208(4):916-922, 2017. e-Pub 2017. PMID: 28140609.
78. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665-670. e-Pub 2017. PMID: 28423171.
79. Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez-MacGregor M, Yang WT. Incremental cancer detection of locoregional restaging with diagnostic mammography combined with whole-breast and regional nodal ultrasound in women with newly diagnosed breast cancer. Acad Radiol 24(2):191-199, 2017. e-Pub 2017. PMID: 27955877.
80. Rauch GM, Adrada BE, Kuerer HM, Van la Parra RF, Leung JW, Yang WT. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol 208(2):290-299, 2017. e-Pub 2017. PMID: 27809573.
81. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. e-Pub 2017. PMID: 29238749.
82. Adrada BE, Rauch GM, Moseley T. Molecular breast imaging: Role as a screening modality. Current Breast Cancer Reports 8(4):230-235, 2016. e-Pub 2016.
83. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
84. Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: Correlation with clinical, histopathologic, biologic features, and local recurrence. Ann Surg Oncol 23(2):482-489, 2016. e-Pub 2016. PMID: 26416712.
85. Jacobsen MC, Dogan BE, Adrada BE, Plaxco JS, Wei W, Son JB, Hazle JD, Ma J. 3-T breast diffusion-weighted magnetic resonance imaging by echo-planar imaging with spectral spatial excitation or with additional spectral inversion recovery: An in vivo comparison of image quality. J Comp Assisted Tomography 39(3):343-348, 2015. e-Pub 2015. PMID: 25695868.
86. Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, Yang W. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 22(4):1111-7, 2015. e-Pub 2015. PMID: 25287438.
87. Adrada BE, Krishnamurthy S, Carkaci S, Posleman-Monetto FE, Ewere A, Whitman GJ. Unusual benign tumors of the breast. J Clin Imaging Sci 5:27, 2015. e-Pub 2015. PMID: 26085959.
88. Miller T, Albarracin C, Carkaci S, Whitman GJ, Adrada BE. Rare malignant tumors of the breast. J Clin Imaging Sci 5:58, 2015. e-Pub 2015. PMID: 26664775.
89. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: Sensitivity, specificity and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 2014. e-Pub 2014. PMID: 25073777.
90. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res 20(14):3870-83, 2014. e-Pub 2014. PMID: 24895461.
91. Muralidhar GS, Markey MK, Bovik AC, Haygood TM, Stephens TW, Geiser WR, Garg N, Adrada BE, Dogan BE, Carkaci S, Khisty R, Whitman GJ. Stereoscopic interpretation of low-dose breast tomosynthesis projection images. J Digitial Imaging 27(2):248-54, 2014. e-Pub 2014. PMID: 24190140.
92. Leong DL, Rainford L, Haygood TM, Whitman GJ, Geiser WR, Adrada BE, Santiago L, Brennan PC. Trend of contrast detection threshold with and without localization. J Digital Imaging 26(6):1099-106, 2013. e-Pub 2013. PMID: 23503988.
93. Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT. (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 40(12):1809-16, 2013. e-Pub 2013. PMID: 23877633.
94. Carkaci S, Geiser WR, Adrada BE, Marquez C, Whitman GJ. How to establish a cost-effective mobile mammography program. Am J Roentgenol 201(5):W691-7, 2013. e-Pub 2013. PMID: 24147498.
95. Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139(3):639-47, 2013. e-Pub 2013. PMID: 23774990.
96. Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi MA, Mawlawi O, Buchholz TA, Yang W. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: Is there a reliable threshold for differentiating benign from malignant?. Acad Radiol 19(5):535-41, 2012. e-Pub 2012. PMID: 22300741.
97. Carkaci S, Santiago L, Adrada BE, Whitman GJ. Screening for breast cancer with sonography. Semin Roentgenol 46(4):285-291, 2011. e-Pub 2011. PMID: 22035671.
98. Haygood TM, Arribas E, Liu QM, Atkinson EN, Brennan PC, Santiago L, Carkaci S, Lane D, Stephens TW, LePetross H, Adrada BE, Davis P, Whitman GJ. Detection of microcalcifications on digital screening mammograms using varying degrees of monitor zooming. AJR Am J Roentgenol 197(4):W761-W768, 2011. e-Pub 2011. PMID: 21940549.
99. Shkumat NA, Springer A, Walker CM, Rohren EM, Yang WT, Adrada BE, Arribas E, Carkaci S, Chuang HH, Santiago L, Mawlawi OR. Investigating the limit of detectability of a positron emission mammography device: A phantom study. Med Phys 38(9):5176-85, 2011. e-Pub 2011. PMID: 21978062.
100. Haygood TM, Arribas E, Brennan PC, Atkinson EN, Herndon M, Dieber J, Geiser W, Santiago L, Mills CM, Davis P, Adrada BE, Carkaci S, Stephens TW, Whitman GJ. Conspicuity of microcalcifications on digital screening mammograms using varying degrees of monitor zooming. Acad Radiol 16(12):1509-17, 2009. e-Pub 2009. PMID: 19896068.
101. Adrada BE, Arribas E, Gilcrease M, Yang WT. Invasive micropapillary carcinoma of the breast: Mammographic, sonographic, and magnetic resonance imaging features. AJR Am J Roentgenol 193(1):W58-63, 2009. e-Pub 2009. PMID: 19542384.
102. Seth S, Sun R, White JB, Ravenberg E, Yam C, Lim B, Litton JK, Tripathy D, Valero V, Damodaran S, Arun B, Ueno NT, Lucci A, Thompson A, Mittendorf E, Rauch GM, Adrada B, Candelaria R, Ding Q, Powell RT, Abuhadra NK, Piwnica-Worms H, Zhang J, Song X, Symmans WF, Huo L, Futreal A, Draetta G, Chang JT, Moulder S. Comprehensive molecular profiling identifies features of disease resistance to neoadjuvant chemotherapy in triple-negative breast cancer. Nature Medicine.
103. Guirguis MS, Adrada B, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Perez F, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Huo L, Litton J, Valero V, Hung KK, Arun B, Mohamed R, Sun J, Korkut A, Xu Z, Pashapoor S, White J, Son JB, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. JCO.

Invited Articles

1. Patel MM, Adrada BE. Hereditary Breast Cancer: BRCA Mutations and Beyond. Radiol Clin North Am 62(4):627-642, 2024. e-Pub 2024. PMID: 38777539.
2. Patel M, Adrada BE, Fowler AM, Rauch GM. Molecular breast imaging and positron emission mammography. PET Clin 18(4):487-501, 2023. e-Pub 2023. PMID: 37258343.
3. Adrada BE, Candelaria R, Rauch GM. Molecular breast imaging for the staging and evaluation of response to therapy in breast cancer. Top Magn Reson Imaging 26(5):211-218, 2017. e-Pub 2017. PMID: 28961570.
4. Adrada BE, Candelaria R, Rauch GM. Magnetic resonance imaging for the staging and evaluation of response to therapy in breast cancer. Magn Reson 26(5):211-218, 2017. e-Pub 2017. PMID: 28961570.
5. Huang ML, Adrada BE, Candelaria R, Thames D, Dawson D, Yang WT. Stereotactic breast biopsy: Pitfalls and pearls. J Vasc Interv Radiol 17(1):32-39, 2014. e-Pub 2014. PMID: 24636329.
6. Carkaci S, Santiago L, Adrada BE, Whitman GJ. Screening for breast cancer with sonography. Semin Roentgenol 46(4):285-91, 2011. e-Pub 2011. PMID: 22035671.

Manuals, Teaching Aids, Other Teaching Publications

1. Moseley TW, Adrada BE, Arribas EM. Phyllodes tumors- documents for clinical scenario appropriate use criteria/ qualified provider-led entity: Houston, TX, 2019.
2. Moseley TW, Adrada BE, Arribas EM. Breast cancer noninvasive- documents for clinical scenario appropriate use criteria/ qualified provider-led entity: Houston, TX, 2019.

Other Articles

1. Patel, MM, Adrada, BE, Nia, ES, Kapoor, MM, Khazai, L, Guirguis, MS, Perez, F, Moseley, T, Arribas, E Multimodality Imaging of Breast Cancer Recurrence Post Breast Conservation Therapy. Current Radiology Reports 12(2):9-18, 2024.
2. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM Tumor necrosis by pretreatment breast MRI: Association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. PMID: 32920733.
3. Santiago L, Adrada BE, Caudle AS, Clemens MW, Black DM, Arribas EM The role of three-dimensional printing in the surgical management of breast cancer. J Surg Oncol 120(6), 2019. PMID: 31441070.
4. Rauch GM, Adrada BE Comparison of breast magnetic resonance imaging with molecular breast imaging in breast cancer screening, diagnosis, staging, and treatment response evaluation. Magn Reson Imaging Clin N Am 26(2):273-280, 2018. PMID: 29622132.
5. Santiago L, Adrada BE, Huang ML, Wei W, Candelaria RP Breast cancer neoplastic seeding in the setting of image-guided needle biopsies of the breast. Breast Cancer Res Treat 166(1):29-39, 2017. PMID: 28730339.
6. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ Pseudoangiomatous stromal hyperplasia of the breast: Multimodality review with pathologic correlation. Curr Probl in Diagn Radiol 46(2):130-135, 2017. PMID: 26949063.
7. Adrada BE, Whitman GJ, Crosby MA, Carkaci S, Dryden MJ, Dogan BE Multimodality imaging of the reconstructed breast. Curr Probl in Diagn Radiol 44(6):487-95, 2015. PMID: 26118619.
8. Adrada BE, Wu Y, Yang W Hyperechoic lesions of the breast: Radiologic-histopathologic correlation. AJR Am J Roentgenol 200(5):W518-30, 2013. PMID: 23617519.
9. Adrada BE, Carkaci S, Whitman GJ Case of the Season: Large b-cell lymphoma involving both breasts. Semin Roentgenol 46(4):242-4, 2011. PMID: 22035665.

Abstracts

1. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting response to neoadjuvant systemic therapy in triple-negative breast cancer for personalized medicine via mathematical modeling and quantitative MR imaging. Joint Center for Computational Oncology - 4th Annual Research Retreat, 2023. e-Pub 2023.
2. Johnson HM, Smith BD, Rauch GM, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Moseley TW, Leung JWT, Huang M, Candelaria RP, Adrada BE, Arribas E, la Parra RFD, Hung KK, Bedrosian I, Teshome M, Sun SX, Hwang RF, Miggins MV, Piotrowski M, Refinetti AP, Ehlers RA, Colen JS, Loveland-Jones C, Lesnikowski BA, Samiian L, Chong C, Shaitelman SF, Mitchell MP, Kuerer HM. Eliminating breast surgery for invasive cancer following neoadjuvant systemic therapy (NST): Prospective multicenter clinical trial first planned feasibility report. Western Surgical Association, 2023. e-Pub 2023.
3. Mohamed RM, Panthi B, Adrada BE, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. Multi-parametric MRI-based radiomics models from tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium 2022 Abstract Report:3955-3960, 2022. e-Pub 2022.
4. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada BE, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodard WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. HER2–01: Clinical and molecular characteristics of HER2–low/zero early stage triple–negative breast cancer. San Antonio Breast Cancer Symposium:1464-1469. e-Pub 2022.
5. Mohamed RM, Panthi B, Adrada BE, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch G. A pre-operative dynamic contrast enhanced MRI-based radiomics models as predictors of treatment response after neoadjuvant systemic therapy in triple negative breast cancer patients. San Antonio Breast Cancer Symposium 2022 Abstract Report:4025-4028, 2022. e-Pub 2022.
6. Panthi B, Mohamed RM, Adrada BE, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Rauch G. Longitudinal DCE-MRI radiomic models for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium 2022 Abstract Report:4020-4024, 2022. e-Pub 2022.
7. Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HTC, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, White J, Wei P, Son JB, K-P H, Panthi B, Pagel M, Hunt KK, Thompson AM, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G. DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer. San Antonio Breast Cancer Symposium 2022 Abstract Report:357-361, 2022. e-Pub 2022.
8. Le-Petross HTC, Bhavsar S, Scoggins ME, Sun J, Bui T, Shin K, Stafford J, Carlson III R, Adrada BE. Safety of breast MRI under general anesthesia. San Antonio Breast Cancer Symposium 2022 Abstract Report:900-901, 2022. e-Pub 2022.
9. Mohamed RM, Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Patel MM, Elshafeey NA, Pashapoor S, Zhou Z, Son JB, K-P H, Le-Petross HC, Leung JWT, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley TW, Perez F, White J, Chen H, Sun J, Wei P, Litton J, Valero V, Tripathy D, Yam C, Pagel MD, Ma J, Rauch GM. Multi-parametric MRI-based radiomics models for early neoadjuvant systemic treatment response prediction in triple negative breast cancer (TNBC). Radiological Society of North America Annual Meeting, 2022. e-Pub 2022.
10. Adrada BE, Moseley TW, Rauch GM, Patel MM, Perez F, Kapoor MM, Nia ES, Scoggins ME, Khazai L, Arribas E, Guirguis MS. The many faces of triple negative breast cancer. Radiological Society of North America Annual Meeting. e-Pub 2022.
11. Moseley T, Perard R, Guirguis M, Patel M, Nia E, Kapoor M, Perez F, Arribas E, Posleman F, Adrada BE. Moving beyond alphabet soup using root cause analysis (RCA) and failure mode and effects analysis (FMEA) to learn from errors in the breast imaging clinic. Radiological Society of North America Scientific Assembly and Annual Meeting Program, 2022. e-Pub 2022.
12. Guirguis MS, Adrada BE, Patel M, Perez F, Candelaria RP, Yang WT, Sun J, Mohamed RMM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley TW, Musall B, White J, Zhou Z, Pashapoor S, Wei P, Son JB, K-P H, Panthi B, Pagel MD, Huo L, Hunt KK, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Early prediction of chemoresistance versus excellent response in triple negative breast cancer patients with DCE-MRI. Radiological Society of North America Annual Meeting, 2022. e-Pub 2022.
13. Perez F, Arribas E, Nia E, Guirguis M, Kapoor M, Patel M, Adrada BE, Moseley T. A comprehensive look at disparities in breast cancer in the non-hispanic black, hispanic, and transgender community in the united states and what policy changes should be considered. Radiological Society of North America Scientific Assembly and Annual Meeting Program. e-Pub 2022.
14. Guirguis M, Moseley T, Qingping D, Nia E, Patel M, Perez F, Kapoor M, Arribas E, Adrada B. All roads lead to rome:  Multi-modality imaging of benign and malignant pathologies of the nipple areolar complex. Radiological Society of North America Scientific Assembly and Annual Meeting Program, 2022. e-Pub 2022.
15. Patel M, Adrada B, Nia E, Kapoor M, Khazai L, Guirguis M, Perez F, Moseley T, Arribas E. Multimodality imaging of breast cancer recurrence. Radiological Society of North America Scientific Assembly and Annual Meeting Program. e-Pub 2022.
16. Adrada BE, Guirguis MS, Patel MM, Perez F, Candelaria RP, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HC, Leung JWT, Whitman GJ, Lane DL, Scoggins ME, Moseley T, Musall B, White J, Zhou Z, Wei P, Son JB, K-P H, Panthi B, Pagel M, Huo L, Hunt K, Ravenberg E, Thompson A, Litton J, Valero V, Tripathy D, Moulder S, Yam C, Ma J, Rauch GM. Development of a combined model for early prediction of pathologic complete response (pCR) in triple negative breast cancer (TNBC) undergoing neoadjuvant therapy (NAT). Radiological Society of North America Annual Meeting, 2022. e-Pub 2022.
17. Zhou Z, Adrada BE, Candelaria RP, Mohamed RM, Pashapoor S, Panthi B, Son JB, Xu Z, K-P H, Guirguis MS, Yang W, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Moseley T, Scoggins ME, Patel MM, Perez F, White J, Litton J, Valero V, Tripathy D, Yam C, Pagel MD, Ma J, Rauch GM. Deep learning using pre-treatment MRI's and clinical information for predication complete response to neoadjuvant systemic therapy in triple negative breast cancer. Radiological Society of North America Annual Meeting, 2022. e-Pub 2022.
18. Elshafeey N, Adrada BE, Candelaria RP, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Mahmoud HS, Son JB, Kotrosou A, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Litton JK, Huo L, Tripathy D, Valero V, Thompson AM, Moulder S, Yang WT, Pagel MD, Ma JF, Rauch GM. Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. Cancer Res 81(4), 2021. e-Pub 2021.
19. Rauch GM, Drukker K, Elshafeey N, Mohamed RMM, Boge M, Adrada BE, Candelaria RP, Salama M, Shkatova I, Giger M, Yang WT. Quantitative dynamic contrast-enhanced (DCE) MRI radiomic phenotypes for prediction of nodal and distal metastasis in breast cancer patients. Cancer Res 81(4), 2021. e-Pub 2021.
20. Rauch GM, Adrada BE, Candelaria RP, Elshafeey N, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RMM, Son JB, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HC, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma J, Yang WT, Moulder S. Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. Cancer Res 81(4), 2021. e-Pub 2021.
21. Zhang S, Rauch G, Adrada BE, Boge M, Mohammed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Lane DL, Leung JWT, Scoggins M, Spak D, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall B, Miyoshi M, Wang XZ, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Thompson A, Moulder S, Candelaria R, Yang W, Ma J, Pagel M. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: A pilot study. Cancer Res 81(4), 2021. e-Pub 2021.
22. Seth S, Rauch GM, Adrada B, Piwnica-Worms H, Hou L, Thompson AM, Symmans WF, Lim B, White J, Draetta GF, Futreal A, Chang J, Moulder S. A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443). Cancer Res 81(4), 2021. e-Pub 2021.
23. Abuhadra N, Yam C, Sun R, Huo L, White J, Ravenberg E, Adrada B, Sahin A, Litton J, Lim B, Ueno NT, Arun B, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Lucci A, Mittendorf E, Moulder S, Chang J. Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT). Cancer Res 81(4), 2021. e-Pub 2021.
24. Kotrotsou A, Elshafeey N, Adrada B, Sun J, Candelaria R, Abdelhafez A, Yang W, Mohamed R, Boge M, Willis B, Musall B, Bum Son J, Zhang S, Thompson A, Tripathy D, Moseley T, Litton J, Whitman G, Le-Petross H, Valero V, Santiago L, Lane D, Lim B, Leung J, Scoggins M, Spak D, Arribas E, White J, Ravenberg E, Cardenas-Rodriguez J, Wei P, Moulder S, Rauch G, Pagel M. Reliability of pharmacokinetic (PK) parameters by DCE-MRI for prediction of neoadjuvant systemic treatment (NAST) response in triple negative breast cancer (TNBC) patients: A comparison of three analysis methods. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020, 2020. e-Pub 2020.
25. Rauch GM, Adrada BE, Candelaria RP, Elshafeey N, Abdelhafez AH, Musall BC, Sun J, Boge M, Mohamed RM, Son JB, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HC, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Huo L, Litton JK, Valero V, Tripathy D, Thompson AM, Pagel MD, Ma J, Yang WT, Moulder S. Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
26. Rauch G, Adrada B, Candelaria R, Elshafeey N, Mohamed R, Boge M, Moseley T, Whitman G, Le-Petross H, Santiago L, Lane D, Leung J, Spak D, Valero V, Litton J, Huo L, Tripathy D, Mittendorf E, Thompson A, Arribas E, Scoggins M, Musall B, Kotrotsou A, Sun J, Bum Son J, White J, Zhang S, Hwang K, Wei P, Moulder S, Pagel M, Ma J, Yang W. Longitudinal MR imaging findings in triple negative breast cancer (TNBC) patients undergoing neoadjuvant systemic therapy (NAST) stratified by tumor infiltrating lymphocytes (TIL) levels. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020, 2020. e-Pub 2020.
27. Adrada BE, Guirguis M, Mosley T. Nuts and bolts of MRI-Guided biopsy. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
28. Rauch GM, Drukker K, Elshafeey N, Mohamed RMM, Boge M, Adrada BE, Candelaria RP, Salama M, Shkatova I, Giger M, Yang WT. Quantitative Dynamic Contrast-Enhanced (DCE) MRI radiomic phenotypes for prediction of nodal and distal metastasis in breast cancer patients. San Antonio Breast Cancer Symposium. e-Pub 2020.
29. Musall B, Abdelhafez A, Adrada B, Son JB, Candelaria R, Sun J, Yang W, Santiago L, Whitman G, Le-Petross H, Moseley T, Lane D, Leung J, Scoggins M, Spak D, Arribas E, Mahmoud H, White J, Hwang K, Elshafeey N, Mohamed R, Boge M, Kotrotsou A, Zhang S, Damodaran S, Litton J, Valero V, Tripathy D, Thompson A, Wei P, Moulder S, Pagel M, Ma J, Rauch G. Radiomic features of quantitative apparent diffusion coefficient (ADC) maps from peritumoral regions (PTRs) as predictors of early treatment response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
30. Seth S, Rauch GM, Adrada B, Hou L, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, White JB, Symmas WF, Draetta GF, Futreal A, Chang J, Moulder SL. A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443). San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
31. Sanin MP, Saldarriaga C, Norena Rengifo BD, Adrada BE, Martinez de Vega V, Luengas A. Breast MRI findings of complications in breast augmentation- What the radiologist should know. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
32. Elshafeey N, Adrada B, Kotrotsou A, Abdelhafez A, Candelaria R, Yang W, Sun J, Mohamed R, Boge M, Mahmoud H, Musall B, Bum Son J, Tripathy D, Santiago L, Thompson A, Valero V, Whitman G, Litton J, Lim B, Le-Petross H, Leung J, Lane D, Arribas E, Spak D, Scoggins M, Moseley T, Ueno N, Zhang S, White J, Moulder S, Hwang K, Wei P, Pagel M, Ma J, Rauch G. Radiomic phenotypes from ultrafast dynamic contrast enhanced (DCE) MRI for prediction of the treatment response to neoadjuvant systemic therapy (NAST) of triple negative breast cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020, 2020. e-Pub 2020.
33. Zhang S, Rauch G, Adrada B, Abdelhafez A, Bum Son J, Yang W, Sun J, Boge M, Mohamed R, Elshafeey N, White J, Musall B, Moseley T, Whitman G, Le-Petross H, Santiago L, Lane D, Leung J, Scoggins M, Spak D, Arribas E, Ravenberg E, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang K, Litton J, Thompson A, Candelaria R, Moulder S, Ma J, Pagel M. Comparison of chemical exchange saturation transfer (CEST) MRI acquisition and analysis for early neoadjuvant systemic therapy (NAST) treatment response assessment in triple negative breast cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
34. Nia ES, Adrada BE, Whitman GJ, Candelaria RP, Krishnamurthy S, Bassett R, Arribas EM. MRI appearance of pseudoangiomatous stromal hyperplasia (pash) with pathological correlation. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
35. Candelaria R, Adrada B, Deanna L, Roland B, Lumarie S, Rauch G, Moseley T, Scoggins M, Thompson A, Ravenberg E, White J, Spak D, Le-Petross H, Arribas E, Whitman G, Leung J, Litton J, Mittendorf E, Huo L, Valero V, Moulder S, Yang W. BI-RADS ultrasound lexicon descriptors and tumor-infiltrating lymphocytes in triple negative breast cancer. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020, 2020. e-Pub 2020.
36. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed R, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Lane DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, K-P H, Thompson A, Moulder SL, Candelaria RP, Yang W, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: A pilot study. San Antonio Breast Cancer Symposium. e-Pub 2020.
37. Guirguis M, Adrada BE, Le-Petross HC, Dryden M, Rauch G, Moseley T, Whitman GJ. Challenging cases in breast localization: A multimodality approach. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
38. Elshafeey NA, Adrada BE, Candelaria RP, Abdelhafez AH, Mussall BS, Sun J, Boge M, Mohamed RMM, Mahmoud HS, Son JB, Kotrosou A, Zhang S, Leung J, Lane D, Scoggins M, Spak D, Arribas E, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, White JB, Ravenberg E, Hwang KP, Wei P, Liton JK, Huo L, Tripathy D, Valero V, Thompson AM, Moulder S, Yang WT, Pagel MD, Ma J, Rauch GM. Radiomic phenotypes from Dynamic Contrast-Enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in Triple Negative Breast Cancer (TNBC) patients. San Antonio Breast Cancer Symposium. e-Pub 2020.
39. Zhang S, Rauch G, Adrada B, Boge M, Mohammed R, Yang W, Nlshafeey N, Sun J, Abdelhafez A, Bum Son J, White J, Moseley T, Whitman G, Le-Petross H, Santiago L, Lane D, Leung J, Scoggins M, Spak D, Arribas E, Ravenberg E, Musall B, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, Hwang K, Litton J, Thompson A, Moulder S, Candelaria R, Ma J, Pagel M. Assessment of early response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: Pilot study. Radiological Society of North America Scientific Assembly and Annual Meeting Program 2020. e-Pub 2020.
40. Moulder SL, Basset RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Jk L, Thompson AM, Mittendorf EA, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). J Clin Oncol 38(15), 2020. e-Pub 2020.
41. Basho RK, Yam C, White JB, Zhao L, Huo L, Mittendorf EA, Thompson AM, Litton JK, Arun B, Lim B, Valero V, Tripathy D, Zhang JH, Adrada BE, Santiago L, Ravenberg E, Moulder SL, Damodaran S. Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. J Clin Oncol 38(15), 2020. e-Pub 2020.
42. Abuhadra N, Sun R, Litton JK, Rauch G, Thompson AM, Lim B, Adrada B, Mittendorf E, White JB, Ravenberg E, Damodaran S, Candelaria RP, Arun B, Ueno NT, Santiago L, Murthy RK, Ibrahim N, Symmans WF, Moulder S, Huo L. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). J Clin Oncol 38(15), 2020. e-Pub 2020.
43. Adrada BE, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins ME, Spak DA, Leung JWT, Damodaran S, Lim, Valero V, White J, Thompson AM, Litton JK, Moulder SL, Ma J, Yang WT, Rauch GM. Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients. Cancer Res 80(4), 2020. e-Pub 2020.
44. Damodaran S, Litton JK, Hess KR, Eppig CT, Grzegorzewski KJ, Meric-Bernstam F, Wistuba II, White JB, Rauch GM, Candelaria RP, Adrada BE, Lim B, Moulder SL, Tripathy D. A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations. San Antonio Breast Cancer Symposium 80(4), 2020. e-Pub 2020.
45. Seth S, Juo L, Vasaikar S, Rauch G, Lim B, White J, Adrada B, Piwnca-Worms H, Ueno NT, Thompson AM, Mittendorf E, Tripathy D, Litton JK, Symmans WF, Draetta G, Futreal A, Chang J, Moulder S. Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). San Antonio Breast Cancer Symposium 80(4), 2020. e-Pub 2020.
46. Adrada BE, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins ME, Spak DA, Leung JWT, Damodaran S, Lim, Valero V, White J, Thompson AM, Litton JK, Moulder SL, Ma J, Yang WT, Rauch GM. Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium 80(4), 2020. e-Pub 2020.
47. Garber HR, Rauch GM, Adrada BE, Candelaria RP, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun BK, Ueno NT, Valero V, Ibrahim NK, Murthy RK, Tripathy D, Piwnica-Worms H, Symmans WF, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). Cancer Res 80(4), 2020. e-Pub 2020.
48. Abuhadra NK, Lim B, Thompson A, Mittendorf E, Hess KR, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang W, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder S, Huo L. Serial TILs: Evaluating the role of midtreatment tumor infiltrating lymphoctyes (TIL) in predicting pathologic complete response. San Antonio Breast Cancer Symposium 80(4), 2020. e-Pub 2020.
49. Garber HR, Rauch GM, Adrada BE, Candelaria RP, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun BK, Ueno NT, Valero V, Ibrahim NK, Murthy RK, Tripathy D, Piwnica-Worms H, Symmans WF, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). San Antonio Breast Cancer Symposium 80(4), 2020. e-Pub 2020.
50. Candelaria R, Hess K, Lane D, Santiago L, Moulder S, Yang W, Thompson A, Rauch G, Huang M, Arribas E, Scoggins M, Moseley T, Le-Petross H, Spak D, Whitman G, Leung J, Valero V, Damodaran S, Litton J, White J, Adrada BE. Predicting pathologic complete response with ultrasound tumor characteristics in triple negative breast cancer patients. Radiological Society of North America Annual Meeting, 2019. e-Pub 2019.
51. Musall B, Ma J, Adrada BE, Abdel Hameed A, Candelaria R, Yang W, Hess K, Santiago L, Whitman G, Le-Petross H, Moseley T, Arribas E, Lane D, Leung J, Scoggins M, Pagel M, Hwang K, Son J, White J, Litton J, Damodaran S, Lim B, Wilillis B, Mahmoud H, Megahed A, Thompson A, Moulder S, Rauch G. Quantitative tumor volumes by fast dynamic contrast enhanced (DCE) MRI predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC). Radiological Society of North America Scientific Assembly and Annual Meeting Program, 2019. e-Pub 2019.
52. Abdel Hameed A, Adrada BE, Musall B, Ma J, Candelaria R, Yang W, Hess K, Santiago L, Whitman G, Le-Petross H, Moseley T, Arribas E, Lane D, Scoggins M, Leung J, Pagel M, Hwang K, Son J, Litton J, Damodaran S, Lim B, White J, Mahmoud H, Valero V, Thompson A, Moulder S, Rauch G. Tumor necrosis at baseline dynamic contrast enhanced (DCE) MRI for prediction of neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC) patients. Radiological Society of North America Scientific Assembly and Annual Meeting Program, 2019. e-Pub 2019.
53. Adrada BE, Candelaria R, Hess K, Moulder S, Santiago L, Valero V, Arribas E, Moseley T, Lane D, Scoggins M, Le-Petross H, Spak D, Huang M, Litton J, Thompson A, White J, Whitman G, Leung J, Yang W, Rauch G. Precision imaging: Early ultrasound evaluation (US) to identify excellent responders to neoadjuvant. Radiological Society of North America Scientific Assembly and Annual Meeting Program, 2019. e-Pub 2019.
54. Crespo J, Sahil S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada BE, Rauch G, Sentihil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Characterization of the LAR subtype triple negative breast cancer population. Cancer Res 79(13), 2019. e-Pub 2019.
55. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. J Clin Oncol 37(15):572, 2019. e-Pub 2019.
56. Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Futreal A, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). J Clin Oncol 37(15), 2019. e-Pub 2019.
57. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. J Clin Oncol 37(15), 2019. e-Pub 2019.
58. Hobbs E, Yang F, Kumar T, Contreras A, Cuentas ERP, Garber H, Scoggins M, Adrada BE, Whitman GJ, Arun B, Minttendorf EA, Litton JK. Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. J Clin Oncol 37(15), 2019. e-Pub 2019.
59. Crespo J, Seth S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada BE, Rauch GM, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Bora L. Characterization of the LAR-subtype triple-negative breast cancer population. 2019 American Association for Cancer Research (AACR), 2019. e-Pub 2019.
60. Seth S, Huo L, Rauch G, Lau R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans WF, Draetta G, Futreal AP, Moulder S, Chang JT. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). Cancer Res 79(4), 2019. e-Pub 2019.
61. Adrada BE, Valero V, Reddy SM, Barcenas CH, Candelaria R, Wei W, Rauch GM. Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC). Cancer Res 79(4), 2019. e-Pub 2019.
62. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. Cancer Res 79(4), 2019. e-Pub 2019.
63. Patel M, Dawson D, Adrada BE, Lane D, Santiago L. Troubleshooting on combined 2D/3D stereotactic/tomosynthesis breast biopsy units. Association of University Radiologists 66th Annual Meeting 2018, 2018. e-Pub 2018.
64. Litton JK, Scoggins M, Hess KR, Adrada BE, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA plus ). J Clin Oncol 36(15), 2018. e-Pub 2018.
65. Yam C, Hess K, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy R, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder S. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). J Clin Oncol 36(15):593, 2018. e-Pub 2018.
66. Moulder S, Hess K, Candelaria RP, Rauch GM, Santiago L, Adrada BE, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). J Clin Oncol 36(15), 2018. e-Pub 2018.
67. Rauch GM, Adrada BE, Kappadath C, Candelaria RP, Huang ML, Santiago L, Moseley T, Scoggins ME, Knudtson JD, Lopez BP, Hess KR, Krishnamurthy S, Moulder S, Valero V, Yang W. Quantitative assessment of tumor response to neoadjuvant chemotherapy in women with locoregional invasive breast cancer using Tc99m sestamibi molecular breast imaging - preliminary results. Cancer Res 78(4), 2018. e-Pub 2018.
68. Echeverria GV, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Rauch G, Adrada BE, Candelaria R, Santiago L, Thompson A, Litton J, Moulder S, Symmans F, Chang JT, Piwnica-Worms H. A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment. Cancer Res 78(4), 2018. e-Pub 2018.
69. Rauch GM, Li H, Zhu H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf E, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. Cancer Res 78(4):618, 2018. e-Pub 2018.
70. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Euno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen receptor positivity is associated with nodal disease in triple negative breast cancer. Cancer Res 78(136), 2018. e-Pub 2018.
71. Rauch GM, Zhu H, Li H, Adrada BE, Santiago L, Candelaria R, Wang H, Leung J, Litton J, Wu Y, Murthy R, Mittendorf E, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. Cancer Res 78(4):1181, 2018. e-Pub 2018.
72. Yam C, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendork EA, Ueno N, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans F, Moulder SL, Yang W. Risk of Needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer (TNBC). Cancer Res 78(4):988, 2018. e-Pub 2018.
73. Damodaran S, Hess K, Rauch GM, Adrada BE, Santiago L, Litton J, Mittendorf E, Lim B, Ueno N, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, Moulder SL. A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT). Cancer Res 77(13), 2017. e-Pub 2017.
74. Lopez B, Rauch GM, Adrada BE, Backe S, Hess K, Kappadath S. Quantification of in vivo tumor uptake in clinical molecular breast imaging (MBI) examinations. Med Phys 44(6):3263, 2017. e-Pub 2017.
75. Moseley TW, Adrada BE, Rauch GM. Molecular breast imaging. Cancer Study and Therapy Conference, 2017. e-Pub 2017.
76. Arribas E, Huang M, Adrada BE, Rauch GM, Santiago. The atypical malignant axillary lymph node in breast cancer patients. American Roentgen Ray Society, 2017. e-Pub 2017.
77. Lopez B, Rauch GM, Adrada BE, Backe S, Hess K, Kappadath S. Quantifying Tc-99msestamibi uptake in breast tumors using molecular breast imaging. Medical Physics Journal 44(6):3263, 2017. e-Pub 2017.
78. Hegason T, Moulder S, Thompson A, Symmans WF, Hess K, Yang W, Adrada BE, Rauch GM, Gilcrease M, Mittendorf EA, Tripathy D, Ueno NT. A phase IIB study of neoadjuvant PaCT regimen (panitumumab in combination with carboplatin and paclitaxel) for anthracycline resistant triple-negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 77(4), 2016. e-Pub 2016.
79. Huang ML, Hess K, Candelaria RP, Eghtedari M, Adrada BE, Sneige N, Fornage BD. Comparison of the accuracy of ultrasound guided biopsy of breast masses performed with 18-gauge, 16-gauge and 14-gauge automated cutting needle biopsy devices. European Congress of Radiology Program, 2015. e-Pub 2015. PMID: 27844099.
80. Carkaci S, Geiser W, Adrada B, Whitman G. How to establish a successful mobile mammography program. Am J Roentgenol 198(5), 2012. e-Pub 2012.
81. Adrada BE, Wei W, Quraishi A, Yi M, Hunt K, Gilcrease M, Yang W. Synchronous bilateral breast cancer: Mammography, sonography, and histopathologic correlation. Am J Roentgenol 194(5), 2010. e-Pub 2010.
82. Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi M, Mawlavi O, Buchholz T, Yang W. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer patients: Is there a reliable threshold for differentiating benign from malignant?. Am J Roentgenol 194(5), 2010. e-Pub 2010.

Book Chapters

1. Rauch GM, Guirguis MS, Adrada BE. After breast conservation therapy. In: CORE Requisites: Breast Imaging. Elsevier, 212-232, 2022.
2. Huang ML, Adrada BE, Yang WT. Breast cancer screening. In: Breast Cancer, 3 Ed.